Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04787042
Title	Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Recruitment	Active, not recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Simcha IL-18, Inc.
Indications	renal cell carcinoma lung small cell carcinoma stomach cancer endometrial cancer lung non-small cell carcinoma cervical cancer transitional cell carcinoma skin squamous cell carcinoma hepatocellular carcinoma head and neck squamous cell carcinoma triple-receptor negative breast cancer esophageal cancer melanoma ovarian cancer Advanced Solid Tumor Merkel cell carcinoma
Therapies	Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067
Age Groups:	adult \| senior
Covered Countries	USA